Literature DB >> 32433400

Clinical Utility of Histological and Radiological Evaluations of Tumor Necrosis for Predicting Prognosis in Pancreatic Cancer.

Masashi Kudo1,2,3, Tatsushi Kobayashi4, Naoto Gotohda2, Masaru Konishi2, Shinichiro Takahashi2, Shin Kobayashi2, Motokazu Sugimoto2, Satoshi Okubo2, John Martin5, Horacio Cabral5, Genichiro Ishii1,3, Motohiro Kojima1.   

Abstract

OBJECTIVES: Tumor necrosis is often found in pancreatic ductal adenocarcinoma (PDAC). Objective histological assessment and adequate radiological detection of necrosis could be used as biomarkers for therapeutic decision. However, standardized clinical utility of necrosis remains unknown. Here, we aimed to determine the prognostic potential of histological and radiological evaluations of necrosis.
METHODS: We investigated histological necrosis in 221 patients, who underwent surgery for PDAC, and classified its size as small (≤5 mm) or large (>5 mm). We also evaluated poorly enhanced areas on preoperative computed tomography to assess their ability for predicting histological necrosis and postoperative prognosis.
RESULTS: Tumor necrosis was found in 115 patients (52%) and was related to tumor area, lymph node metastasis, and lymphovascular invasion. Size of necrosis was significantly associated with tumor area, perimeter of necrosis, circularity of necrosis, number of ruptured cancer glands, and presence of collagen bundle (P < 0.05 for all). Both presence of necrosis and their size were strongly correlated to postoperative prognosis. Patients with poorly enhanced areas showed worse prognosis (P < 0.01).
CONCLUSIONS: Our findings underline the capacity of histological and radiological assessment of tumor necrosis for prognosis prediction in PDAC.

Entities:  

Mesh:

Year:  2020        PMID: 32433400     DOI: 10.1097/MPA.0000000000001539

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  1 in total

1.  Histological tumor necrosis in pancreatic cancer after neoadjuvant therapy.

Authors:  Masashi Kudo; Genichiro Ishii; Naoto Gotohda; Masaru Konishi; Shinichiro Takahashi; Shin Kobayashi; Motokazu Sugimoto; John D Martin; Horacio Cabral; Motohiro Kojima
Journal:  Oncol Rep       Date:  2022-05-18       Impact factor: 4.136

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.